The International Academy of Clinical Research (IAoCR) has now released its draft GxP Training Guidelines for public consultation following initial review and feedback from over 35 not-for-profit and membership organisations around the world.
Over 60 training and quality assurance personnel have already requested a copy of the draft GxP Training Guidelines which are being made freely available by the IAoCR in order to involve the widest number of interested parties from within the clinical research industry.
As CEO at IAoCR, Jacqueline Johnson North explains: “We have always felt that it is crucial to engage the entire industry in order to create the most cohesive, relevant set of GxP Training recommendations possible. The more people who review this document and provide feedback, the more valuable it will be to all of us. We would like these training guidelines to be applicable to all members of the industry across all sectors and we actively encourage everyone to get involved. We are very pleased with the interest shown to date and hope this accurately reflects the level of commitment from the industry.”
Following the launch of this initiative, executives from the IAoCR have been invited to speak at a number of conferences later this year and on into 2013. Jacqueline will be speaking at the European Training Conference in Lisbon in April 2013 and the IAoCR’s Principal Director, Martin Robinson will be speaking at the French Biomedical Data Management Association conference in Paris in November 2012.
The GxP Training Guidelines have been produced by the International Academy of Clinical Research with input from an independent taskforce of industry experts from the international clinical research community. The aim of the Guidelines is to provide best practice recommendations for the training life-cycle to enable organisations to be able to demonstrate individuals’ competence. The document contains minimum requirements for best practice in training and will be used to help introduce consistent training standards across the industry. It is hoped that the guidelines will be voluntarily adopted across the industry and that this will provide a global framework for best practice.
To receive a copy of the draft Guidelines and information on how to provide feedback complete the webform on www.iaocr.com/gxpt The deadline for feedback is 30 September 2012. After this time, the guidelines will be finalised ready for publication in October 2012.
For more information, please visit www.iaocr.com.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.